Belgium: Researchers have reported that age does not appear to influence how postmenopausal women with osteoporosis respond to romosozumab therapy, based on real-world evidence from a ...

What is believed to be the first study of a nutraceutical published in a medical journal has revealed promising results for more than 10 million Americans suffering from osteoporosis and 43 million ...

Primary biliary cholangitis (PBC) is a chronic cholestatic disorder in which symptoms exert a direct influence on patients’ quality of life. Beyond pruritus and fatigue, patients with PBC are also ...

On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...

Romosozumab use in adults with osteoporosis was associated with a 21% reduction in risk for osteoarthritis, particularly knee osteoarthritis, compared with teriparatide use. Researchers used a ...

Osteoporosis drug romosozumab showed no increased risk for the development of cardiovascular (CV) events compared with anabolic osteoporosis drugs, contrary to its black box warning, new research ...

Among patients with severe postmenopausal osteoporosis unresponsive to long-term denosumab, addition of romosozumab improved lumbar spine bone mineral density. Denosumab combined with romosozumab may ...

New data from multiple countries confirm the effectiveness of romosozumab, the dual-acting osteoporosis treatment that increases bone formation and decreases bone resorption. Findings were presented ...

Romosozumab was not associated with increased cardiovascular risks among patients with osteoporosis when compared with bisphosphonate use. Romosozumab does not appear to significantly increase the ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...

Romosozumab is a new type of drug that is highly effective at treating this condition by blocking the protein sclerostin, which is produced by bone cells and negatively impacts bone density.